- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
California gov. signs error bill
California Governor Grey Davis has signed into law a bill that will require California hospitals to submit a "formal" plan for reducing medication-related errors in their facilities to the state by Jan. 1, 2002.
California Governor Grey Davis has signed into law a bill that will require California hospitals to submit a "formal" plan for reducing medication-related errors in their facilities to the state by Jan. 1, 2002. Once the plan is approved by the state, the facility must implement it on or before Jan. 1, 2005.
The new law applies to general acute care hospitals, special hospitals and surgical clinics.
For the purposes of the law, a "medication-related error" means "any preventable medication-related event that adversely affects a patient in a facility ⦠and that is related to professional practice, or healthcare products, procedures, and systems, including, but not limited to, prescribing, prescription order communications, product labeling, packaging and nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
